3 October 2017Americas

FDA issues new guidance to boost generic competition

The US Food and Drug Administration (FDA) has issued new guidance as part of its bid to target the barriers to generic drug competition.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More features

Gilead awarded $30m over counterfeit HIV drug scheme

EPO invalidates human milk patent after Nestle opposition

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic